These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17406366)

  • 21. Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center.
    Yildiz O; Ozguroglu M; Yanmaz T; Turna H; Serdengecti S; Dogusoy G
    Med Oncol; 2010 Dec; 27(4):1050-6. PubMed ID: 19908171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
    Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
    Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
    Tirosh A; Nilubol N; Patel D; Kebebew E
    Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
    Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
    Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.
    Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J
    Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
    Klöppel G
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
    Artale S; Giannetta L; Cerea G; Maggioni D; Pedrazzoli P; Schiavetto I; Napolitano M; Veronese S; Bramerio E; Gambacorta M; Vanzulli A; Pisconti S; Pugliese R; Siena S
    Anticancer Res; 2005; 25(6C):4463-9. PubMed ID: 16334127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
    Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
    PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the cytologic diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Sigel CS
    Cancer Cytopathol; 2018 Dec; 126(12):980-991. PubMed ID: 30485690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
    Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.
    Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M
    Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations of E-cadherin, alpha-catenin and beta-catenin expression in neuroendocrine tumors of the gastrointestinal tract.
    Li CC; Xu B; Hirokawa M; Qian Z; Yoshimoto K; Horiguchi H; Tashiro T; Sano T
    Virchows Arch; 2002 Feb; 440(2):145-54. PubMed ID: 11964044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
    Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ploidy, proliferative activity, p53 and bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis.
    Santinelli A; Ranaldi R; Baccarini M; Mannello B; Bearzi I
    Pathol Res Pract; 1999; 195(7):467-74. PubMed ID: 10448663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
    Dasari A; Mehta K; Byers LA; Sorbye H; Yao JC
    Cancer; 2018 Feb; 124(4):807-815. PubMed ID: 29211313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
    Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
    Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal carcinoids: characterization by site of origin and hormone production.
    Onaitis MW; Kirshbom PM; Hayward TZ; Quayle FJ; Feldman JM; Seigler HF; Tyler DS
    Ann Surg; 2000 Oct; 232(4):549-56. PubMed ID: 10998653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.